Belgium· BE-AMP-SAM154567-00
Nasasinuspray Anti-allergie 0.5 mg/ml
A levocabastine product containing levocabastine hydrochloride, registered in Belgium by Kenvue Belgium. The same ATC class is registered in 10 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Levocabastine is registered in 10 of 19 countries.
Countries holding a registration under ATC R01AC02 (levocabastine), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 6 of them publish a price we can compare per daily dose
Levocabastine · ATC R01AC02
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Levocabastine Hydrochloride
- Manufacturer
- Kenvue Belgium
- Country
- Belgium (BE)
- ATC code
- R01AC02
- ATC class
- Levocabastine
- Defined daily dose
- 0.6 mg, N
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb0251272
- be_apb4990628
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Levocabastine in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandLivostinMcNeil / JNTL Consumer Health (Finland) Oy
- SpainBILINA 0,5 mg/ml SUSPENSIÓN PARA PULVERIZACIÓN NASALEsteve Pharmaceuticals S.A.
- IcelandLivostinMcNeil Sweden AB
- NetherlandsLivocab 0,5 mg/ml neusspray, suspensieKenvue Netherlands B.V.
- GermanyLevocabastinDermapharm Ag
- United KingdomLivostin 0.05% nasal sprayNovartis Pharmaceuticals UK Ltd
- FranceALLERGIFLASH 0,05 %, collyre en solutionLABORATOIRE CHAUVIN
- SwedenLivocab 50 mikrogram/dos Nässpray, suspensionOrifarm AB
Authorised across Europe · EMA
The same active substance is authorised in 15 EEA countries. Names it is sold under:
- Austria · Levocamed, Livostin
- Czechia · Livostin
- Germany · Levocabastin, Levocamed
- Denmark · Benaliv
- Spain · Bilina, Reactine
- Finland · Livostin
- France · Allergiflash, Levofree
- Greece · Livostin
- Iceland · Livostin
- Italy · Levoreact, Levoreact Oftalmico
- Luxembourg · Livostin, Nasasinuspray Anti-Allergie
- Netherlands · Livocab
- Norway · Livostin
- Sweden · Livostin
- Slovakia · Livostin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c515cf81-9614-4355-9c06-c8bf47c8b23e GET /v1/drugs/c515cf81-9614-4355-9c06-c8bf47c8b23e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Nasal spray, suspension",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Nasasinuspray Anti-allergie 0.5 mg/ml",
"name_fr": "Nasasinuspray Anti-allergie 0.5 mg/ml",
"name_nl": "Nasasinuspray Anti-allergie 0.5 mg/ml",
"amp_code": "SAM154567-00",
"strengths": [
"0.5400",
"0.5400",
"0.5400",
"0.5000",
"0.5000",
"0.5000",
"0.2950",
"0.1500",
"8.6600",
"50.0000",
"5.3800",
"1.0000"
],
"pack_count": 1,
"substances": [
"Levocabastine Hydrochloride",
"Levocabastine",
"Benzalkonium Chloride",
"Disodium Edetate",
"Disodium Hydrogen Phosphate Anhydrous",
"Propylene Glycol",
"Sodium Dihydrogen Phosphate Monohydrate",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Levocabastine",
"authorisation_numbers": [
"BE154567"
]
}See everything about levocabastine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.